中文

博济医药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-25
ItemAmountY/Y
Revenue¥0.22B+58.5%
Gross profit¥0.06B
Operating income¥0.02B
Net income¥0.02B+243.3%
Gross margin28.5%Net margin 7.3%
Revenue Q/Q-22.6%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.16B71.5%
R&D¥0.01B5.4%
SG&A¥0.03B11.7%
Tax & other¥0.00B1.6%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

科隆股份九强生物凯发电气道氏技术正业科技金盾股份迦南科技中光防雷伊之密苏试试验南华仪器ST浩丰

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies